In the present study, we examined the activity of human CYP2S1 in the metabolism of nicotine and in the activation of three potent carcinogens in cigarette smoke, 4- (Gibson and Skett, 1994) . Although many CYP enzymes have the highest expression level in the liver, some CYP enzymes are expressed predominantly in extrahepatic tissues. Since the toxicity of a given compound is tightly linked to its metabolic fate in the target tissue, it is believed that the metabolic activation in situ of carcinogens/toxicants by extrahepatic CYP enzymes is critical for tissue-specific carcinogenicity/toxicity (Ding and Kaminsky, 2003) .
Recently, a novel CYP enzyme, CYP2S1 has been identified. The CYP2S1 gene is localized in the CYP2 gene cluster on chromosome 19q13.2, encoding of protein which consists of 504 amino acid residues with a derived molecular mass of 55.8 kD. CYP2S1 is predominantly expressed in human extrahepatic tissues including trachea and lung as well as in the stomach, small intestine, spleen and skin (Rylander et al., 2001; Rivera et al., 2002; Smith et al., 2003) . It is inducible by dioxin in a human lung epithelial cell line A549 (Rivera et al., 2002) . Except for all-trans retinoic acid (Smith et al., 2003) , the substrates of CYP2S1 are unknown. The high level of CYP2S1 expression in human respiratory tissues suggests that this enzyme may play a role in the metabolism of environmental chemicals that humans are exposed to through the airways.
Cigarette smoking is the most important etiological factor of human lung cancer (Hoffmann et al., 1994; Spivack et al., 1997) . It has been reported that about 87% of human lung cancers are caused by cigarette smoking (American Cancer Society, 2001 ). This article has not been copyedited and formatted. The final version may differ from this version. (Hecht, 1999) . These include potent lung carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK, a tobacco-specific nitrosamine), benzo[a]pyrene (BaP, a polycyclic aromatic hydrocarbon), and 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP, a heterocyclic amine) (Hecht, 1999 (Hecht, , 2002 . All these carcinogens require CYP-mediated metabolic activation to exert their carcinogenicity and toxicity.
To understand the toxicological and physiological roles of CYP2S1, it is critical to identify its substrates. As part of our effort to explore the metabolic role of CYP2S1 for environmental carcinogens/toxicants, the present work examined the activity of CYP2S1 in the metabolic activation of NNK and BaP by using the Chinese Hamster Ovary (CHO) cells that stablely express human CYP2S1 cDNA. We also determined the activities of herterologously expressed CYP2S1 proteins in metabolizing nicotine and PhIP. Our results demonstrate that human CYP2S1 is not involved in the metabolism of these chemicals present in cigarette smoke.
Materials and Methods
Chemicals and reagents. NNK (99% purity) was purchased from ChemSyn (Lenexa, KS). PhIP (98% purity) was purchased from Toronto Research Chemicals (Ontario, Canada). BaP (>97% purity), (-)-nicotine (99% purity), (-)-cotinine (99% purity) and cotinine-methyl-d 3 (99 atom % D) were obtained from Sigma-Aldrich (St. Louis, MO).
Human lung first-strand cDNA library was from BD Biosciences Clontech (Palo Alto, CA Cloning of CYP2S1 cDNA. A full-length CYP2S1 cDNA was amplified from the human lung first-strand cDNA library by a reported nested PCR method with the same outer primers (Rylander et al., 2001) . The nested PCR primers were designed using the This article has not been copyedited and formatted. The final version may differ from this version. (known to activate BaP) were used as positive controls.
Cytotoxicity was determined by a modified MTS assay using the Cell Titer 96 ® AQ uenous non-radioactive cell proliferation assay kit. For each 24-well plate, the MTS mixture was prepared by mixing 1 ml of MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfopheny)-2H-tetrazolium, inner salt), 50 µ l of PMS (phenazine methosulfate) and 11 ml of HAM F12 nutrient mixture. After NNK or BaP treatment, the medium in each well was removed and 0.5 ml of MTS mixture was added.
The cells were incubated with MTS mixture at 37℃ in dark for 30 minutes. ) and stored at -80℃ before use. The CYP2S1 protein level in the microsomes was determined by immunoblot analysis as described previously. Microsomal P450 content was determined by reduced CO-difference spectrum after solubilization (Omura and Sato, 1964) . The CO-difference spectra were recorded using an UV/Visible spectrophotometer (Shimadzu UV 160U, Japan). 
Metabolism of nicotine and

Results and Discussion
Expression of human CYP2S1 proteins in Flp-In CHO cells and in Sf9 insect cells
We used the Flp-In CHO cells to generate the transfectants that stablely express CYP2S1.
These cells contain a Flp Recombination Target (FRT) site in their genome and allow for
This article has not been copyedited and formatted. The final version may differ from this version. from the transfection will express the same level of the transgene. In our study, colonies of stable transfectants that were resistant to hygromycin B were selected and the integration of CYP2S1 cDNA in their genomic DNA was confirmed by PCR with CYP2S1-specific primers (data not shown). Immunoblotting with a monoclonal antibody against 6×Histag, which was fused with the C-terminal of CYP2S1 protein, further demonstrated that CYP2S1 proteins were successfully expressed in these stable transfectants (Fig. 1A) . There was no significant difference in the levels of CYP2S1
protein expression among different antibiotic-resistant colonies (Fig. 1A) . This result is consistent with the working mechanism of the Flp-In system since in all the stable transfectants the transgenes are integrated at the same FRT site.
To produce sufficient amount of CYP2S1 proteins for the metabolism study, the recombinant baculoviruses containing CYP2S1 cDNA were used to infect Sf9 insect cells. Immunoblot analysis of the microsomal proteins prepared from the infected Sf9 cells showed a single protein band with the predicted molecular weight (~55 kD) of human CYP2S1 protein (Fig. 1B) . In addition, microsomes prepared from the CYP2S1-expressing Sf9 cells displayed a distinctive absorption peak at 450 nm, a characteristic of CYP enzymes, in reduced CO-difference spectrum analysis (Fig. 1C ). These results demonstrate that CYP2S1 proteins were also successfully expressed in the Sf9 cells.
NNK-and BaP-induced toxicity in CHO cells expressing CYP2S1
This article has not been copyedited and formatted. The final version may differ from this version. µ M). The selection of these concentrations was based on either a reported study (Townsend et al., 2002) or our pilot experiments. Cells transfected with the pcDNA5 vector alone (containing no CYP cDNA) were used as a negative control. Since CYP2A13 and CYP1A1 are known to be the major enzymes for the metabolic activation of NNK and BaP, respectively (Su et al., 2000; Doehmer et al., 1999) , the Flp-In CHO cells expressing either CYP2A13 (CHO-2A13) or CYP1A1 (CHO-1A1) were used as corresponding positive controls. The cytotoxicity was determined by a widely used MTS assay which measures the cell viability. The working principle of MTS assay is that the mitochondrial dehydrogenase released during cell death can reduce MTS to a colored formazan product that can be measured directly by a plate-reader for absorption at 490nm There was no significant cell death induced by NNK and BaP treatment in the cells transfected with the pcDNA5 vector alone. This is consistent with the fact that these cells do not express the CYP enzymes that metabolically activate NNK and BaP. NNK and BaP caused a dose-dependent decrease in cell viability in the CHO-2A13 and CHO-1A1 cells, respectively. In contrast, there was no change in the viability in the CHO-2S1 cells treated with either NNK or BaP, even at the highest concentrations (Fig. 2) . The result of MTS assay was confirmed by the microscopic examination. As shown in Fig. 3 
Metabolism of nicotine and PhIP by CYP2S1
The major pathway of nicotine metabolism in humans is to form cotinine through Coxidation. The first step is catalyzed by the CYP system to produce the intermediate nicotine-∆ -1'(5') -imminium ion, which is further oxidized to cotinine by cytosolic aldehyde oxidase (Williams et al., 1990; Peterson et al., 1987; Gorrod et al., 1982) . Previous studies have shown that CYP2A6 is the major enzyme responsible for metabolizing nicotine to cotinine in humans (Cashman, 1992) . Recently, we have demonstrated that CYP2A13 is at least as efficient as CYP2A6 for this reaction (Bao et al., 2004) . On the other hand, human CYP1A2 is the key enzyme catalyzing the activation of PhIP to form N-hydroxy PhIP, which is a major and carcinogenic metabolite (Wallin et al., 1990) . To does not catalyze the metabolism of nicotine to cotinine and of PhIP to N-hydroxy PhIP.
Conclusion
To assess the toxicological roles of individual human CYP enzymes, identification of their environmental substrates is a necessary step. Until now, all-trans retinoic acid is the only known substrate of CYP2S1 (Smith et al., 2003) . The predominant expression of CYP2S1 in human respiratory tissues and its induction by dioxin in mouse lung and human lung cell line A549 lead to the speculation that CYP2S1 is involved in the metabolism of a number of carcinogens that humans are exposed to through airways.
While this hypothesis may still be valid, results of our studies clearly exclude the role of CYP2S1 in the metabolism of nicotine and in the metabolic activation of three major carcinogens in cigarette smoke. The endogenous and environmental substrates as well as the functional roles of CYP2S1 remain to be determined. 
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